Skip to content
2000
Volume 20, Issue 6
  • ISSN: 1574-8855
  • E-ISSN: 2212-3903

Abstract

Milk thistle seeds contain silymarin, a powerful hepatoprotective compound known to shield liver cells from toxins, increase glutathione levels, and promote cell regeneration. Silybin, one of the key components of silymarin, is highly valued by herbalists due to its minimal side effects. Silymarin is ubiquitously distributed across diverse geographic regions, encompassing Europe, Africa, Asia, Australia, North and South America, India, and China. Silymarin comprises an array of compounds, specifically silydianin, isosilybin A, isosilybin B, silybin A, and silydianin flavonoids. Its pharmacological applications are multifaceted, including antidiabetic, hepatoprotective, hypocholesterolemic, antihypertensive, anti-inflammatory, anticancer, and antioxidant properties. Milk thistle seeds additionally exhibit anti-spasmodic, neuroprotective, antiviral, immunomodulant, and cardioprotective characteristics. They can even enhance milk secretion and help treat uterine disorders. Such an in-depth inquiry is poised to facilitate the meticulous assessment by researchers of its efficacy in therapeutic applications. Additionally, silymarin exhibits changes in cellular transporter, P-glycoprotein, as well as estrogenic and nuclear receptors. It also impedes apoptosis and follicular development during fertilization, making it a promising option in complementary medicine. This documented evidence is useful in safeguarding vital organs against an array of maladies, encompassing cancer, fertilization, hepatotoxicity, nephrotoxicity, viral hepatitis challenges, neurotoxicity, depressive disorders, and pulmonary and prostate disorders. This scholarly article undertakes a comprehensive exploration of the pharmacognostic, morphological, ethnobotanical, and pharmacological importance of .

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdth/10.2174/0115748855309458240725055702
2024-07-30
2025-10-23

  • From This Site

    /content/journals/cdth/10.2174/0115748855309458240725055702
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KarthikeyanA. ShanthiV. NagasathayaA. Preliminary phytochemical and antibacterial screening of crude extract of the leaf of Adhatoda vasica. L.Int. J. Green Pharm.200931788010.4103/0973‑8258.49381
     [Google Scholar]
  2. HoganF.S. KrishnegowdaN.K. MikhailovaM. KahlenbergM.S. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer.J. Surg. Res.20071431586510.1016/j.jss.2007.03.08017950073
     [Google Scholar]
  3. PolyakS.J. FerenciP. PawlotskyJ.M. Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection.Hepatology20135731262127110.1002/hep.2617923213025
     [Google Scholar]
  4. FerenciP. ScherzerT.M. KerschnerH. RutterK. BeinhardtS. HoferH. Schöniger-HekeleM. HolzmannH. Steindl-MundaP. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.Gastroenterology200813551561156710.1053/j.gastro.2008.07.07218771667
     [Google Scholar]
  5. KarimiG. VahabzadehM. LariP. RashediniaM. MoshiriM. “Silymarin”, a promising pharmacological agent for treatment of diseases.Iran. J. Basic Med. Sci.201114430831723492971
     [Google Scholar]
  6. SameeA. AmirR.M. AhmadA. WattoF.M. AliM. AzamM.T. SheerazM. FatimaH. ZahoorZ. ZahidM. AshrafH. Effectiveness of milk thistle on human body against diseases: A comprehensive review.Scholars Bulletin20239281810.36348/sb.2023.v09i02.002
     [Google Scholar]
  7. LeeD.Y.W. LiuY. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, Isolated from Silybum marianum (milk thistle).J. Nat. Prod.20036691171117410.1021/np030163b14510591
     [Google Scholar]
  8. DixitN. BabootaS. KohliK. AhmadS. AliJ. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches.Indian J. Pharmacol.200739417217910.4103/0253‑7613.36534
     [Google Scholar]
  9. GovindP. SahniY.P. A review on hepatoprotective activity of silymarin.Int. J. Res. Ayurveda Pharm.2011217579
     [Google Scholar]
  10. PandeyG.P. Hepatogenic Effect of Some Indigenous Drugs on Experimental Liver Damage.PhD Thesis, Science University Jabalpur, 1990.
     [Google Scholar]
  11. GreenleeH. AbascalK. YarnellE. LadasE. Clinical applications of Silybum marianum in oncology.Integr. Cancer Ther.20076215816510.1177/153473540730172717548794
     [Google Scholar]
  12. PradhanS.C. GirishC. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine.Indian J. Med. Res.2006124549150417213517
     [Google Scholar]
  13. RadkoL. CybulskiW. Application of silymarin in human and animal medicine.J Pre-Clin Clin Res.2007112226
     [Google Scholar]
  14. AjayK. DeepaI. PurnimaA. NeerajV. Silymarin: A comprehensive review.Pharmacogn. Rev.200935116124
     [Google Scholar]
  15. TůmováL. TůmaJ. MegušarK. DoležalM. Substituted pyrazinecarboxamides as abiotic elicitors of flavolignan production in Silybum marianum (L.) gaertn cultures in vitro.Molecules201015133134010.3390/molecules1501033120110894
     [Google Scholar]
  16. LuperS. A review of plants used in the treatment of liver disease: part 1.Altern. Med. Rev.1998364104219855566
     [Google Scholar]
  17. SallerR. MeierR. BrignoliR. The use of silymarin in the treatment of liver diseases.Drugs200161142035206310.2165/00003495‑200161140‑0000311735632
     [Google Scholar]
  18. BergerJ. KowdleyK.V. Is silymarin hepatoprotective in alcoholic liver disease?J. Clin. Gastroenterol.200337427827910.1097/00004836‑200310000‑0000214506381
     [Google Scholar]
  19. GillessenA. SchmidtH.H.J. Silymarin as supportive treatment in liver diseases: A narrative review.Adv. Ther.20203741279130110.1007/s12325‑020‑01251‑y32065376
     [Google Scholar]
  20. PorwalO. Mohammed AmeenM.S. AnwerE.T. UthirapathyS. AhamadJ. TahsinA. Silybum marianum (Milk Thistle): Review on Its chemistry, morphology, ethno medical uses, phytochemistry and pharmacological activities.J. Drug Deliv. Ther.20199519920610.22270/jddt.v9i5.3666
     [Google Scholar]
  21. BijakM. Silybin, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.)—Chemistry, bioavailability, and metabolism.Molecules20172211194210.3390/molecules2211194229125572
     [Google Scholar]
  22. ValenzuelaA. GarridoA. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin.Biol. Res.19942721051128640239
     [Google Scholar]
  23. AlthagafyH.S. Meza-AviñaM.E. OberliesN.H. CroattM.P. Mechanistic study of the biomimetic synthesis of flavonolignan diastereoisomers in milk thistle.J. Org. Chem.201378157594760010.1021/jo401137723876147
     [Google Scholar]
  24. KurkinV.A. Phenylpropanoids from medicinal plants: Distribution, classification, structural analysis, and biological activity.Chem. Nat. Compd.200339212315310.1023/A:1024876810579
     [Google Scholar]
  25. BiedermannD. VavříkováE. CvakL. KřenV. Chemistry of silybin.Nat. Prod. Rep.20143191138115710.1039/C3NP70122K24977260
     [Google Scholar]
  26. BaiT.C. ZhuJ.J. HuJ. ZhangH.L. HuangC.G. Solubility of silybin in aqueous hydrochloric acid solution.Fluid Phase Equilib.20072541-220421010.1016/j.fluid.2007.03.009
     [Google Scholar]
  27. van WenumE. JurczakowskiR. LitwinienkoG. Media effects on the mechanism of antioxidant action of silybin and 2,3-dehydrosilybin: role of the enol group.J. Org. Chem.201378189102911210.1021/jo401296k24006901
     [Google Scholar]
  28. NapolitanoJ.G. LankinD.C. GrafT.N. FriesenJ.B. ChenS.N. McAlpineJ.B. OberliesN.H. PauliG.F. HiFSA fingerprinting applied to isomers with near-identical NMR spectra: the silybin/isosilybin case.J. Org. Chem.20137872827283910.1021/jo302720h23461697
     [Google Scholar]
  29. HanY.H. LouH.X. RenD.M. SunL.R. MaB. JiM. Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process.J. Pharm. Biomed. Anal.20043451071107810.1016/j.jpba.2003.12.00215019041
     [Google Scholar]
  30. MontiD. GažákR. MarholP. BiedermannD. PurchartováK. FedrigoM. RivaS. KřenV. Enzymatic kinetic resolution of silybin diastereoisomers.J. Nat. Prod.201073461361910.1021/np900758d20297826
     [Google Scholar]
  31. NyiredyS. SamuZ. SzücsZ. GulácsiK. KurtánT. AntusS. New insight into the biosynthesis of flavanolignans in the white-flowered variant of Silybum marianum.J. Chromatogr. Sci.2008462939610.1093/chromsci/46.2.9318366865
     [Google Scholar]
  32. AbouzidS. Silymarin, natural flavonolignans from milk thistle.Phytochemicals—A Global Perspective of Their Role in Nutrition and Health.London, UKIntech201225527210.5772/26027
     [Google Scholar]
  33. SamuZ. NyiredyS. Baitz-GácsE. VargaZ. KurtánT. DinyaZ. AntusS. Structure Elucidation and Antioxidant Activity of (−)-isosil and reisolated from silybum marianum L.Chem. Biodiversity20041111668167710.1002/cbdv.200490125
     [Google Scholar]
  34. PatelCJ. TyagiS. Clinical benefits of milk thistle (Silybum marianum): a review.J Drug Discov Ther.201311811
     [Google Scholar]
  35. PandeyG.P. SrivastavaD.N. MadhuriS. Hepatogenic effect of Livol, Eclipta alba and Silybum marianum on paracetamol-induced liver damage in rabbits.Int J Green Pharm.2006113538
     [Google Scholar]
  36. GovindP. Hepatogenic effect of some herbal drugs on paracetamol-altered serum transaminases activity in rabbits.Biol Med.200722202205
     [Google Scholar]
  37. GovindP. Hepatogenic efficacy of Livol, Eclipta alba and Silybum marianum against paracetamol-altered serum protein levels.Biol Med.2008316265
     [Google Scholar]
  38. GovindP. Hepatogenic effects of some indigenous drugs on paracetamol-damaged liver in mice.Biol. Med. (Aligarh)2010543235
     [Google Scholar]
  39. KwonDY. JungYS. KimSJ. KimYS. ChoiDW. KimYC. Alterations in sulfur amino acid metabolism in mice treated with silymarin: a novel mechanism of its action involved in enhancement of the antioxidant defense in liver.Planta Med.20137912997100210.1055/s‑0032‑1328704
     [Google Scholar]
  40. RamasamyK. AgarwalR. Multitargeted therapy of cancer by silymarin.Cancer Lett.2008269235236210.1016/j.canlet.2008.03.05318472213
     [Google Scholar]
  41. PolyakS.J. MorishimaC. LohmannV. PalS. LeeD.Y.W. LiuY. GrafT.N. OberliesN.H. Identification of hepatoprotective flavonolignans from silymarin.Proc. Natl. Acad. Sci. USA2010107135995599910.1073/pnas.091400910720231449
     [Google Scholar]
  42. TägerM. DietzmannJ. ThielU. NeumannK.H. AnsorgeS. Restoration of the cellular thiol status of peritoneal macrophages from CAPD patients by the flavonoids silibinin and silymarin.Free Radic. Res.200134213715110.1080/1071576010030013111264891
     [Google Scholar]
  43. KondylisV. KumariS. VlantisK. PasparakisM. The interplay of IKK, NF-κB and RIPK 1 signaling in the regulation of cell death, tissue homeostasis and inflammation.Immunol. Rev.2017277111312710.1111/imr.1255028462531
     [Google Scholar]
  44. GharagozlooM. VelardiE. BruscoliS. AgostiniM. Di SanteM. DonatoV. AmirghofranZ. RiccardiC. Silymarin suppress CD4+ T cell activation and proliferation: Effects on NF-κB activity and IL-2 production.Pharmacol. Res.201061540540910.1016/j.phrs.2009.12.01720056147
     [Google Scholar]
  45. KimB.R. SeoH.S. KuJ.M. KimG.J. JeonC.Y. ParkJ.H. JangB.H. ParkS.J. ShinY.C. KoS.G. Silibinin inhibits the production of pro-inflammatory cytokines through inhibition of NF-κB signaling pathway in HMC-1 human mast cells.Inflamm. Res.2013621194195010.1007/s00011‑013‑0640‑124045679
     [Google Scholar]
  46. MorishimaC. ShuhartM.C. WangC.C. PaschalD.M. ApodacaM.C. LiuY. SloanD.D. GrafT.N. OberliesN.H. LeeD.Y.W. JeromeK.R. PolyakS.J. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection.Gastroenterology20101382671681.e2, 681.e1-681.e210.1053/j.gastro.2009.09.02119782083
     [Google Scholar]
  47. MannaS.K. MukhopadhyayA. VanN.T. AggarwalB.B. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis.J. Immunol.1999163126800680910.4049/jimmunol.163.12.680010586080
     [Google Scholar]
  48. KimM. YangS.G. KimJ.M. LeeJ.W. KimY.S. LeeJ. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: Analysis of isolated hepatic stellate cells.Int. J. Mol. Med.201230347347910.3892/ijmm.2012.102922710359
     [Google Scholar]
  49. TrappoliereM. CaligiuriA. SchmidM. BertolaniC. FailliP. VizzuttiF. NovoE. ManzanoC. MarraF. LoguercioC. PinzaniM. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells.J. Hepatol.20095061102111110.1016/j.jhep.2009.02.02319398228
     [Google Scholar]
  50. LieberC.S. LeoM.A. CaoQ. RenC. DeCarliL.M. Identification of novel mechanisms of silymarin on the carbon tetrachloride-induced liver fibrosis in mice by nuclear factor-kappaB bioluminescent imaging-guided transcriptomic analysis.Food Chem Toxicol20125051568157510.1016/j.fct.2012.02.025
     [Google Scholar]
  51. LieberC.S. LeoM.A. CaoQ. RenC. DeCarliL.M. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons.J. Clin. Gastroenterol.200337433633910.1097/00004836‑200310000‑0001314506392
     [Google Scholar]
  52. SaliouC. KitazawaM. McLaughlinL. YangJ.P. LodgeJ.K. TetsukaT. IwasakiK. CillardJ. OkamotoT. PackerL. Antioxidants modulate acute solar ultraviolet radiation-induced NF-kappa-B activation in a human keratinocyte cell line.Free Radic. Biol. Med.1999261-217418310.1016/S0891‑5849(98)00212‑39890652
     [Google Scholar]
  53. VargheseL. AgarwalC. TyagiA. SinghR.P. AgarwalR. Silibinin efficacy against human hepatocellular carcinoma.Clin. Cancer Res.200511238441844810.1158/1078‑0432.CCR‑05‑164616322307
     [Google Scholar]
  54. LuP. MamiyaT. LuL.L. MouriA. ZouL.B. NagaiT. HiramatsuM. IkejimaT. NabeshimaT. Silibinin prevents amyloid β peptide-induced memory impairment and oxidative stress in mice.Br. J. Pharmacol.200915771270127710.1111/j.1476‑5381.2009.00295.x19552690
     [Google Scholar]
  55. YounossiZ.M. KoenigA.B. AbdelatifD. FazelY. HenryL. WymerM. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016641738410.1002/hep.2843126707365
     [Google Scholar]
  56. Al-AnatiL. EssidE. ReinehrR. PetzingerE. Silibinin protects OTA-mediated TNF-α release from perfused rat livers and isolated rat Kupffer cells.Mol. Nutr. Food Res.200953446046610.1002/mnfr.20080011019156713
     [Google Scholar]
  57. SallerR. MelzerJ. ReichlingJ. BrignoliR. MeierR. An updated systematic review of the pharmacology of silymarin.Complement. Med. Res.2007142708010.1159/00010058117464157
     [Google Scholar]
  58. KrollD.J. ShawH.S. OberliesN.H. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies.Integr. Cancer Ther.20076211011910.1177/153473540730182517548790
     [Google Scholar]
  59. Davis-SearlesPR. NakanishiY. KimNC. GrafTN. OberliesNH. WaniMC. WallME. AgarwalR. KrollDJ. Milk thistle and prostate cancer: Differential effects of pure flavonolignans from Silybum marianum on antiproliferative endpoints in human prostate carcinoma cells.Cancer Res.200565104448445710.1158/0008‑5472.CAN‑04‑4662
     [Google Scholar]
  60. Darvishi KhezriH. SalehifarE. KosaryanM. AliasgharianA. JalaliH. Hadian AmreeA. Potential effects of silymarin and its flavonolignan components in patients with β-thalassemia major: A comprehensive review in 2015.Adv. Pharmacol. Sci.201620161810.1155/2016/304637326997953
     [Google Scholar]
  61. KaurM. AgarwalR. Silymarin and epithelial cancer chemoprevention: How close we are to bedside?Toxicol. Appl. Pharmacol.2007224335035910.1016/j.taap.2006.11.01117184801
     [Google Scholar]
  62. SiegelA.B. StebbingJ. Milk thistle: early seeds of potential.Lancet Oncol.20131410929930, 70414-7041510.1016/S1470‑2045(13)70414‑523993379
     [Google Scholar]
  63. DeepG. AgarwalR. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer.Cancer Metastasis Rev.201029344746310.1007/s10555‑010‑9237‑020714788
     [Google Scholar]
  64. SinghR.P. AgarwalR. Prostate cancer chemoprevention by silibinin: Bench to bedside.Mol. Carcinog.200645643644210.1002/mc.2022316637061
     [Google Scholar]
  65. PatelN. JosephC. CorcoranG.B. RayS.D. Silymarin modulates doxorubicin-induced oxidative stress, Bcl-xL and p53 expression while preventing apoptotic and necrotic cell death in the liver.Toxicol. Appl. Pharmacol.2010245214315210.1016/j.taap.2010.02.00220144634
     [Google Scholar]
  66. ZhaoJ. Lahiri-ChatterjeeM. SharmaY. AgarwalR. Inhibitory effect of a flavonoid antioxidant silymarin on benzoyl peroxide-induced tumor promotion, oxidative stress and inflammatory responses in SENCAR mouse skin.Carcinogenesis200021481181610.1093/carcin/21.4.81110753220
     [Google Scholar]
  67. TyagiA. AgarwalC. ChanD. AgarwalR. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.Oncol. Rep.2004a11249349910.3892/or.11.2.49314719089
     [Google Scholar]
  68. TyagiA. AgarwalC. HarrisonG. GlodeL.M. AgarwalR. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages.Carcinogenesis2004b2591711172010.1093/carcin/bgh18015117815
     [Google Scholar]
  69. ChuS.C. ChiouH.L. ChenP.N. YangS.F. HsiehY.S. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.Mol. Carcinog.200440314314910.1002/mc.2001815224346
     [Google Scholar]
  70. DeepG. SinghR.P. AgarwalC. KrollD.J. AgarwalR. Silymarin and silibinin cause G1 and G2–M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.Oncogene20062571053106910.1038/sj.onc.120914616205633
     [Google Scholar]
  71. ThelenP. JarryH. RingertR.H. WuttkeW. Silibinin down-regulates prostate epithelium-derived Ets transcription factor in LNCaP prostate cancer cells.Planta Med.200470539740010.1055/s‑2004‑81896515124082
     [Google Scholar]
  72. SzkudelskiT. The mechanism of alloxan and streptozocin action in B cells of the rat pancreas.Physiolog. Res.200150536546
     [Google Scholar]
  73. ShahS.V. BaligaR. RajapurkarM. FonsecaV.A. Oxidants in chronic kidney disease.J. Am. Soc. Nephrol.2007181162810.1681/ASN.200605050017167116
     [Google Scholar]
  74. SotoC. MenaR. LunaJ. CerbónM. LarrietaE. VitalP. UríaE. SánchezM. RecobaR. BarrónH. FavariL. LaraA. Silymarin induces recovery of pancreatic function after alloxan damage in rats.Life Sci.200475182167218010.1016/j.lfs.2004.04.01915325843
     [Google Scholar]
  75. DaviesK.J.A. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems.IUBMB Life2000504-527928910.1080/71380372811327322
     [Google Scholar]
  76. GalhardiF. MesquitaK. MonserratJ.M. BarrosD.M. Effect of silymarin on biochemical parameters of oxidative stress in aged and young rat brain.Food Chem. Toxicol.200947102655266010.1016/j.fct.2009.07.03019647779
     [Google Scholar]
  77. NenciniC. GiorgiG. MicheliL. Protective effect of silymarin on oxidative stress in rat brain.Phytomedicine2007142-312913510.1016/j.phymed.2006.02.00516638633
     [Google Scholar]
  78. BaluchnejadmojaradT. RoghaniM. MafakheriM. Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: Involvement of estrogen receptors and oxidative stress.Neurosci. Lett.2010480320621010.1016/j.neulet.2010.06.03820600617
     [Google Scholar]
  79. MetodiewaD. KośkaC. Reactive oxygen species and reactive nitrogen species: Relevance to cyto(neuro)toxic events and neurologic disorders. An overview.Neurotox. Res.19991319723310.1007/BF0303329012835102
     [Google Scholar]
  80. KarimiG. Saradeghi KeisariM. Evaluation of antidepressant effect of ethanolic and aqueous extracts of Silybum marianum L. Seed in mice.Faslnamah-i Giyahan-i Daruyi200763843
     [Google Scholar]
  81. WangM.J. LinW.W. ChenH.L. ChangY.H. OuH.C. KuoJ.S. HongJ.S. JengK.C.G. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation.Eur. J. Neurosci.200216112103211210.1046/j.1460‑9568.2002.02290.x12473078
     [Google Scholar]
  82. KitturS. WilasrusmeeS. PedersenW.A. MattsonM.P. Straube-WestK. WilasrusmeeC. JubeltB. KitturD.S. Neurotrophic and neuroprotective effects of milk thistle (Silybum marianum) on neurons in culture.J. Mol. Neurosci.200218326527010.1385/JMN:18:3:26512059045
     [Google Scholar]
  83. PeraçoliJ.C. RudgeM.V.C. PeraçoliM.T.S. PeraM.T. OliM. Tumor necrosis factor-alpha in gestation and puerperium of women with gestational hypertension and pre-eclampsia.Am. J. Reprod. Immunol.200757317718510.1111/j.1600‑0897.2006.00455.x17295896
     [Google Scholar]
  84. ChlopčíkováŠ. PsotováJ. MiketováP. ŠimánekV. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans.Phytother. Res.200418210711010.1002/ptr.141515022159
     [Google Scholar]
  85. SotoC. PérezJ. GarcíaV. UríaE. VadilloM. RayaL. Effect of silymarin on kidneys of rats suffering from alloxan-induced diabetes mellitus.Phytomedicine201017141090109410.1016/j.phymed.2010.04.01120579862
     [Google Scholar]
  86. VarziH.N. EsmailzadehS. MorovvatiH. AvizehR. ShahriariA. GiviM.E. Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity in dogs.J. Vet. Pharmacol. Ther.200730547748110.1111/j.1365‑2885.2007.00901.x17803742
     [Google Scholar]
  87. KarimiG. RamezaniM. TahoonianZ. Cisplatin nephrotoxicity and protection by milk thistle extract in rats.Evid. Based Complement. Alternat. Med.20052338338610.1093/ecam/neh10316136217
     [Google Scholar]
  88. KarimiG. Fallah HuseiniH. RamezaniM. TahoonianZ. Protective effect of Silybum marianum (l.) Gaertn. Seeds extract and silymarin against cisplatin-induced acute nephrotoxicity in rats.Faslnamah-i Giyahan-i Daruyi200544245
     [Google Scholar]
  89. KaurG. AtharM. AlamM.S. Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion response.Invest. New Drugs201028570371310.1007/s10637‑009‑9289‑619590824
     [Google Scholar]
  90. AgarwalC. SinghR.P. DhanalakshmiS. TyagiA.K. TecklenburgM. SclafaniR.A. AgarwalR. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells.Oncogene200322518271828210.1038/sj.onc.120715814614451
     [Google Scholar]
  91. LiL.H. WuL.J. JiangY.Y. TashiroS.I. OnoderaS. UchiumiF. IkejimaT. Silymarin enhanced cytotoxic effect of anti-Fas agonistic antibody CH11 on A375-S2 cells.J. Asian Nat. Prod. Res.20079759360210.1080/1028602060088250217943553
     [Google Scholar]
  92. RamakrishnanG. AugustineT.A. JaganS. VinodhkumarR. DevakiT. Effect of silymarin on N-nitrosodiethylamine induced hepatocarcinogenesis in rats.Exp. Oncol.2007291394417431387
     [Google Scholar]
/content/journals/cdth/10.2174/0115748855309458240725055702
Loading
Pharmacognostic, Phytochemical, Ethnobotanical, and Pharmacological Significance of Silybum marianum (Milk Thistle) – A Comprehensive Review
Curr Drug Ther 20, 880 (2025); https://doi.org/10.2174/0115748855309458240725055702
/content/journals/cdth/10.2174/0115748855309458240725055702
/content/journals/cdth/10.2174/0115748855309458240725055702
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): carcinoma; cardioprotective; hepatoprotective; milk thistle; silybin; Silymarin

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test